Health News Releases

  • Today May 4
July 26, 2023 17:35
Aleph Farms Submits First Ever Application for Cultivated Meat in Europe
Aleph Farms, a cellular agriculture company that enhances sustainability, food security and animal welfare in our food systems, today announced that it has submitted an application for regulatory appr
July 26, 2023 17:15
BaroPace Receives Approval for First-in-Human Clinical Trial
BaroPace, Inc., a medical technology company dedicated to using blood pressure to regulate pacemakers for patients with heart failure with preserved ejection fraction and hypertension, announced today
July 26, 2023 10:45
Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),[8] Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced
July 25, 2023 11:30
Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johns
July 25, 2023 11:15
Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
Orthogon Therapeutics LLC, a trailblazer in the field of antiviral therapeutics, today announced a dual victory. Orthogon’s lead molecule has successfully completed acute toxicity studies, marking a p
July 21, 2023 11:45
Kenvue Initiates Quarterly Cash Dividend
Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the third quarter
July 17, 2023 09:30
TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)
TauRx Pharmaceuticals Ltd., a global leader in Tau-based research in Alzheimer’s disease (AD), today announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impa
(Photo: Wyss Center for Bio and Neuroengineering)
July 11, 2023 10:05
Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing
The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appoi
July 07, 2023 09:10
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an antibody license agree
Gachon University Gil Medical Center (Gil Medical Center), a pioneering health provider with many “f
July 06, 2023 13:08
Rimini Support™ Enables Gachon University Gil Medical Center to Advance its Digital Transformation Projects and Continue to Serve the Community as a Trailblazer Hospital
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Sale
July 06, 2023 10:15
First Distribution Agreement Executed with Sonic Healthcare
Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Dougl
GilletteLabs Razor with Exfoliating Bar (Photo: Business Wire)
July 05, 2023 09:30
P&G Grooming Invites Dermatologist Community to Go ‘Skin Deep Into Grooming’ at the 25th World Congress of Dermatology
At this year’s 25th World Congress of Dermatology held in Singapore (July 3rd - 8th), P&G’s Grooming Division will spotlight product solutions routed in 120 years of innovation heritage and scientific
July 04, 2023 17:11
Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4
Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25th World Congress of Dermatology (WCD) in Singapore. The results highlight the rapid onset of action of nemolizum
About Generalized Pustular Psoriasis (Graphic: Business Wire)
July 04, 2023 16:25
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Today, at the 25th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab significantly reduced the risk of GPP
Audience at IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) organized b
July 04, 2023 10:10
Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers
The IMPAHCT (International Meeting on Pulmonary Hypertension Clinical Treatment) event, organized by the pharmaceutical company Ferrer, has brought together more than 150 pulmonologists and cardiologi
July 04, 2023 09:50
After the Great Success Achieved in the United States and Canada, DEKA Launches Three Extraordinary Laser and Microwave Platforms at the World Congress of Dermatology in Singapore
DEKA, a subsidiary of the El.En. Group, a company listed on the Eurostar Next of the Italian Stock Exchange (ELN.MI), specialized in the development and manufacturing of cutting-edge Energy Based Devi
OncoPro Tumoroid Culture Medium Kit (Photo: Business Wire)
June 29, 2023 14:05
Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifica
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climat
June 29, 2023 11:40
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival. This includes new
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative coli
June 29, 2023 09:55
Microba Commences Phase I Clinical Trial for IBD Therapeutic
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Th
Aktana welcomes John Vitalie as Chief Executive Officer (Photo: Business Wire)
June 29, 2023 09:15
Aktana Announces New CEO
Aktana, the leader in intelligent customer engagement for the global life sciences industry, welcomes John Vitalie as Chief Executive Officer. Before joining Aktana, John led global teams across va
June 28, 2023 16:22
WCD 2023: Galderma to Present Extensive Data Demonstrating Enduring Commitment to Delivering Innovative Solutions in Dermatology
Galderma will be presenting 59 abstracts/posters from across its extensive portfolio at the 25th World Congress of Dermatology (WCD), reflecting its unrelenting dedication to delivering innovative sol
June 28, 2023 10:20
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
Organon (NYSE: OGN), a global healthcare company focused on women’s health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report. The report highlights the company’s progres
June 27, 2023 10:15
Galderma Raises Approximately USD 1 Billion for Newly Issued Shares in a Private Placement Round
Galderma, the emerging pure-play dermatology category leader, announced today a private placement of approximately USD 1 billion for newly issued shares, from a group consisting of current shareholder
June 27, 2023 09:55
Vertex Ventures HC Announces $200 Million Fund III to Drive Innovation in Healthcare
Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 million. Fund III will be deployed to support and empo
June 26, 2023 09:00
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (r
25 per page50 per page75 per page100 per page